Relevance of Interleukins 6 and 8 Single Nucleotide Polymorphisms in Prostate Cancer: A Multicenter Study
Table 5
Comparison of haplotype frequencies of IL-6 rs1800795 and IL-8 rs2227306 SNPs in the affected and the control groups.
Haplotype IL-6 rs1800795 and IL-8 rs2227306
Haplotype frequencies (%)
Cancer versus control®
BPH versus control®
Cancer (n = 80)
BPH (n = 80)
Control (n = 80)
1
OR1 (95%CI) (LL–UL)
2
OR2 (95%CI) (LL–UL)
CC versus (CT + GC + GT)
17 (21.3%)
26 (32.5%)
18 (22.5%)
0.848
0.930 (0.439–1.967)
0.158
1.658 (0.821–3.350)
CT versus (CC + GC + GT)
13 (16.3%)
17 (21.3%)
44 (55%)
<0.001
0.159 (0.076–0.333)
<0.001
0.221 (0.110–0.442)
GC versus (CC + CT + GT)
24 (30%)
4 (5%)
2 (2.5%)
<0.001
16.714 (3.794–73.631)
0.414
2.053 (0.365–11.538)
GT versus (CC + CT + GC)
26 (32.5%)
33 (41.3%)
16 (20%)
0.075
1.926 (0.937–3.958)
0.004
2.809 (1.387–5.689)
®: reference group, OR: odds ratio, CI: confidence interval, UL: upper limit, LL: lower limit. OR1, 1: odds ratio and value for comparing between cancer and control. OR2, 2: odds ratio and p value for comparing between BPH and control. Statistically significant at ≤ 0.05.
